查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1464782

雙特異性抗體市場：按作用機制、治療領域和最終用戶 - 2024-2030 年全球預測

Bispecific Antibodies Market by Mechanism of Action (Dual Antigen Targeting, Dual-Blocking Antibodies, T-cell Engagers), Therapeutic Area (Autoimmune Diseases, Infectious Diseases, Neurological Disorders), End-user - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

雙特異性抗體市場規模預計2023年為43.6億美元，2024年達到61.4億美元，預計2030年將達到514.7億美元，複合年成長率為42.24%。

雙特異性抗體 (BsAb) 是一種工程蛋白，可同時結合兩種不同類型的抗原或同一抗原上的兩個不同表位。這種雙標靶能力使它們有別於傳統的單株抗體，傳統的單株抗體是為了結合單一抗原而開發的。雙特異性抗體的主要用途是在治療領域，特別是針對和中和癌細胞。其獨特的能力使效應細胞更接近癌細胞，從而增強免疫系統對抗癌症的能力。此外，它在研究中了解疾病機制的用途與其在開發更有效的自體免疫和發炎疾病治療方法中的應用進一步一致。全球癌症和其他慢性疾病發病率的上升、基因和蛋白質工程技術的進步以及開發和核准新型雙特異性抗體的創新推動了雙特異性抗體市場的成長，其中包括對治療方法的監管支持不斷增加。然而，雙特異性抗體的擴展受到開發雙特異性抗體的高成本和生產雙特異性抗體的複雜性的阻礙。同時，擴大使用雙特異性抗體來治療罕見疾病，以及製藥公司對醫療基礎設施和研發活動的投資增加，正在為雙特異性抗體市場開闢新的途徑。

主要市場統計
基準年[2023] 43.6億美元
預測年份 [2024] 61.4億美元
預測年份 [2030] 514.7億美元
複合年成長率（%） 42.24%

作用機轉：增加對雙抗原標靶的偏好，以盡量減少脫靶效應

雙抗原靶向雙特異性抗體旨在同時結合細胞表面上的兩種不同抗原。該機制透過確保標靶必須存在才能結合來提高選擇性和功效，從而最大限度地減少脫靶效應並改善治療結果。它是癌症等複雜疾病所必需的，其中多種途徑驅動疾病進展。雙重阻斷抗體同時抑制兩種不同訊號傳導途徑的作用。透過抑制兩種不同的配體或受體，這些抗體可以更有效地阻斷病理過程，特別是在癌症和自體免疫疾病等疾病中。在訊號途徑冗餘損害單一標靶藥物功效的情況下，基於需求的雙阻斷抗體偏好變得明顯。 T 細胞接合劑是雙特異性抗體的一個子集，旨在使細胞毒性 T 細胞靠近癌細胞，促進腫瘤的靶向殺傷。在腫瘤學領域，基於需求的 T 細胞參與者偏好尤其強烈，利用患者的免疫系統來對抗癌症的能力可顯著改善治療結果。與這些機制相比，針對雙抗原的雙特異性抗體具有選擇性增加的優點，特別適合具有明確特徵和特異性病理標記的疾病。透過靶向多種途徑，雙抗原阻斷抗體有望改善以途徑冗餘和補償疾病進展機制為特徵的疾病的治療結果。 T 細胞接合劑提供了一種獨特的方法，透過招募免疫系統來對抗腫瘤，並在腫瘤學方面顯示出巨大的潛力，但潛在的免疫介導的毒性需要仔細管理。

治療領域：擴大雙特異性抗體在癌症領域的應用，旨在接觸和破壞癌細胞

雙特異性抗體的雙靶向能力提供了一種強大的機制來攻擊和破壞癌細胞，同時保護健康組織。雙特異性抗體在腫瘤學中的應用範圍廣泛，從標靶化腫瘤抗原到讓免疫效應細胞參與更定向的針對癌症的免疫反應。在自體免疫疾病中，雙特異性抗體（bsAb）代表了一種有前途的標靶免疫治療方法。這些分子經過客製化，可同時結合兩種不同的抗原或表位，精確調節免疫反應。需要實現選擇性免疫抑製而不具有廣泛的免疫抑製作用並降低感染疾病和惡性的風險。雙特異性抗體作用於多個標靶的獨特能力有可能對抗感染疾病，特別是包括愛滋病毒在內的病毒感染疾病，其中逃避免疫系統是一個關鍵挑戰。這些治療方法可以透過同時針對病毒表位和招募免疫細胞來增強抗病毒反應。雙特異性抗體能夠精確靶向神經抗原並促進穿過血腦障壁（BBB），這是神經治療的關鍵挑戰，為神經疾病的治療提供了新途徑。在癌症領域，臨床開發的雙特異性抗體應用最為先進，種類繁多。這是由於對標靶癌症治療的高需求以及該領域的大量投資。與傳統治療方法相比，雙特異性抗體可在自體免疫和神經系統疾病領域提供新穎的作用機制。目前針對感染疾病開發的雙特異性抗體很少，它們代表了一種潛在的突破性治療方法，特別是對於對標準治療有抵抗力的慢性病毒感染疾病。

區域洞察

在強大的研發基礎設施、大量的醫療保健支出和強大的專利組合的支持下，美國處於市場需求和雙特異性抗體開發的前沿。 FDA 的支持性法律規範加速了創新治療方法的核准，並鼓勵對專門從事雙特異性抗體的生物技術公司進行大量投資。在加拿大，人們對雙特異性抗體療法的興趣日益濃厚，研究機構和生物技術新興企業獲得了政府和私人資助。儘管南美雙特異性抗體市場仍處於發展階段，但醫療保健支出的增加、創新癌症治療意識的增強以及醫療基礎設施的改善正在推動該地區的市場擴張，顯示出巨大的成長潛力。在歐盟，重點放在引進先進的治療解決方案，包括雙特異性抗體。新治療方法的核准、高昂的醫療費用以及歐洲藥品管理局 (EMA) 提高患者意識的積極措施正在為 BsAb 創造有利的環境。雙特異性抗體在中東和非洲的採用進展緩慢，主要是由於衛生基礎設施有限和衛生支出較低。然而，阿拉伯聯合大公國和沙烏地阿拉伯等中東國家正在醫療保健領域取得長足進步，這可能為雙特異性抗體市場提供動力。亞太地區雙特異性抗體市場正在顯著成長。這是由於醫療費用飆升、癌症發病率上升以及人們對先進治療的認知不斷增強。中國和日本處於雙特異性抗體研發的前沿。監管改革、醫療基礎設施的擴張以及本地生物技術公司與國際製藥巨頭之間的聯盟是推動亞太市場的關鍵因素。

FPNV定位矩陣

FPNV定位矩陣對於評估雙特異性抗體市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對雙特異性抗體市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1. 雙特異性抗體市場規模及預測如何？

2.雙特異性抗體市場預測期間需要考慮投資的產品、細分市場、應用和領域有哪些？

3. 雙特異性抗體市場的技術趨勢和法規結構是什麼？

4.雙特異性抗體市場主要廠商的市場佔有率為何？

5. 進入雙特異性抗體市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地癌症和其他慢性病的發生率正在上升
      • 基因工程和蛋白質工程技術進展
      • 擴大對創新治療方法的監管支持，以促進新型雙特異性抗體的開發和核准
    • 抑制因素
      • 開發雙特異性抗體成本高
    • 機會
      • 擴大雙特異性抗體在罕見疾病治療的應用
      • 製藥公司增加對醫療保健基礎設施和研發活動的投資
    • 任務
      • 與雙特異性抗體相關的製造複雜性
  • 市場區隔分析
    • 作用機轉：雙抗原標靶化優先以最大限度地減少脫靶效應
    • 治療領域：擴大雙特異性抗體在腫瘤學的應用，攻擊並破壞癌細胞
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章雙特異性抗體市場：按作用機制

  • 雙抗原靶點
  • 雙抑制抗體
  • T 細胞接合器

第7章雙特異性抗體市場：依治療領域

  • 自體免疫疾病
  • 感染疾病
  • 神經系統疾病
  • 腫瘤學

第 8 章雙特異性抗體市場：依最終用戶分類

  • 醫院和專家
  • 研究機構和學術中心

第9章美洲雙特異性抗體市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太雙特異性抗體市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲雙特異性抗體市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 市場佔有率分析（2023）
  • FPNV定位矩陣（2023）
  • 競爭情境分析
    • 阿斯特捷利康共用雙特異性資料，目標是「2.0」癌症管道
    • 美國FDA核准雙特異性療法 TALVEY(TM) (talketamab-TGV) 用於治療曾接受嚴重治療的多發性骨髓瘤患者
    • 輝瑞的 erlanatamab 獲得 FDA 和 EMA 提交接受
  • 戰略分析和建議

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-F97DD5A7DF65

[192 Pages Report] The Bispecific Antibodies Market size was estimated at USD 4.36 billion in 2023 and expected to reach USD 6.14 billion in 2024, at a CAGR 42.24% to reach USD 51.47 billion by 2030.

Bispecific antibodies (BsAbs) are engineered proteins that can simultaneously attach to two different types of antigens or two different epitopes on the same antigen. This dual-targeting ability distinguishes them from traditional monoclonal antibodies developed to bind to a single antigen. The primary applications of bispecific antibodies reside in the therapeutic domain, particularly in targeting and neutralizing cancer cells. Their unique capability allows them to bring effector cells in close proximity to cancer cells, enhancing the immune system's ability to combat cancer. Additionally, their use in research to understand disease mechanisms further aligns with their application in creating more effective treatments for autoimmune and inflammatory diseases. Several factors contribute to the growth of the bispecific antibodies market, including rising incidences of cancer and other chronic illnesses globally, advancements in genetic engineering and protein engineering technologies, and growing regulatory support for innovative therapies for developing and approving novel bispecific antibodies. However, the expansion of bispecific antibodies is hindered by the high costs of the development of bispecific antibodies and the manufacturing complexities associated with bispecific antibodies. On the other hand, expanding usage of bispecific antibodies in the treatment of rare diseases and rising investments in healthcare infrastructure and research & development activities by pharmaceutical companies opens new avenues for the bispecific antibodies market.

KEY MARKET STATISTICS
Base Year [2023] USD 4.36 billion
Estimated Year [2024] USD 6.14 billion
Forecast Year [2030] USD 51.47 billion
CAGR (%) 42.24%

Mechanism of Action: Increasing preference for dual antigen targeting for minimizing off-target effects

Dual antigen-targeting bispecific antibodies are designed to bind to two distinct antigens on the surface of cells simultaneously. This mechanism enhances selectivity and efficacy by ensuring that targets must be present for binding, thereby minimizing off-target effects and improving therapeutic outcomes. It is needed in complex diseases, including cancer, where multiple pathways drive disease progression. Dual-blocking antibodies inhibit the action of two separate signaling pathways simultaneously. By blocking two different ligands or receptors, these antibodies can more effectively shut down pathological processes, especially in diseases such as cancer and autoimmune disorders. Need-based preference for dual-blocking antibodies becomes apparent in conditions where redundancy in signaling pathways can undermine the efficacy of single-target agents. T-cell engagers represent a subset of bispecific antibodies designed to bring cytotoxic T-cells into close proximity with tumor cells, thereby promoting the targeted killing of the tumor. Need-based preference for T-cell engagers is particularly strong in oncology, where the ability to harness the patient's immune system to fight cancer can significantly improve outcomes. In comparing these mechanisms, dual antigen-targeting bsAbs offer the advantage of enhanced selectivity, making them particularly suitable for diseases with well-characterized and specific pathological markers. Dual-blocking antibodies, by targeting multiple pathways, promise improved therapeutic outcomes in diseases characterized by pathway redundancy or compensatory mechanisms of disease progression. T-cell engagers offer a unique approach by mobilizing the immune system against tumors, showing great promise in oncology but requiring careful management of potential immune-mediated toxicities.

Therapeutic Area: Expanding application of bispecific antibodies in oncology for engaging and destroying cancer cells

Oncology remains the most prolific area for the application of bispecific antibodies, with their dual-targeting ability offering a potent mechanism for engaging and destroying cancer cells while sparing healthy tissue. The use of bsAbs in oncology spans targeting tumor antigens to engaging immune effector cells for a more directed immune response against cancer. In autoimmune diseases, bispecific antibodies (bsAbs) pose a promising approach for targeted immunotherapy. These molecules are tailored to bind two different antigens or epitopes simultaneously, allowing precision in modulating immune responses. The need lies in achieving selective immunosuppression without broad immunosuppressive effects, thus reducing the risk of infections and malignancies. The unique capability of bispecific antibodies to engage multiple targets holds potential in combating infectious diseases, particularly viral infections, including HIV, where evasion of the immune system is a significant challenge. These therapies can simultaneously target viral epitopes and recruit immune cells, thereby enhancing the antiviral response. Bispecific antibodies offer a novel pathway in treating neurological disorders by enabling precise targeting of neural antigens and facilitating the cross of the blood-brain barrier (BBB), a significant challenge in neurotherapeutics. The oncology sector exhibits the most advanced application and diverse range of bsAbs under clinical development, which is attributed to the high need for targeted cancer therapies and the significant investment in this area. Autoimmune diseases and neurological disorders represent growing segments where bsAbs can offer novel mechanisms of action compared to traditional therapies. Infectious diseases currently have fewer bsAbs under development and show potential for groundbreaking therapies, especially in chronic viral infections resistant to standard treatment.

Regional Insights

The United States is at the forefront of the market demand and the development of bispecific antibodies, backed by robust R&D infrastructure, significant healthcare spending, and a strong patent portfolio. The FDA's supportive regulatory framework accelerates the approval of innovative therapies, encouraging substantial investments in biotechnology firms focused on BsAbs. Canada showcases a growing interest in bispecific antibody therapies, with research institutions and biotech startups receiving government and private funding. The South American market for bispecific antibodies is in a nascent stage; however, it exhibits potential for significant growth due to increasing healthcare expenditure, rising awareness about innovative cancer treatments, and improving healthcare infrastructure, contributing to the market expansion in this region. In the European Union, there's a strong emphasis on the adoption of advanced therapeutic solutions, including bispecific antibodies. The EMA's (European Medicines Agency) proactive approach to approving novel treatments and high healthcare expenditure and patient awareness fosters a favorable environment for BsAbs. The Middle East and Africa show a slower adoption of bispecific antibodies, primarily due to limited healthcare infrastructure and lower healthcare spending. However, certain countries in the Middle East, such as UAE and Saudi Arabia, are making strides in the healthcare sector, which could provide an impetus to the bispecific antibodies market. The APAC region is witnessing remarkable growth in the bispecific antibodies market, driven by escalating healthcare expenditure, rising cancer incidence, and growing awareness about advanced therapies. China and Japan are at the forefront, spearheading research and development in the bispecific antibodies. Regulatory reforms, expanding healthcare infrastructures, and partnerships between local biotech firms and international pharmaceutical giants are key factors propelling the market in APAC.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Bispecific Antibodies Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Bispecific Antibodies Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Bispecific Antibodies Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adimab, LLC, Affimed GmbH, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Eli Lilly and Company, Emergent BioSolutions Inc., F. Hoffmann-La Roche Ltd., Genmab A/S, Gilead Sciences, Inc., Innovent Biologics, Janssen Global Services, LLC by Johnson & Johnson Pte. Ltd., MacroGenics, Inc., Merck KGaA, Mereo Biopharma Group PLC, Merus N.V., Novartis AG, Pfizer Inc., Pieris Pharmaceuticals, Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., TG Therapeutics, Inc., and Xencor, Inc..

Market Segmentation & Coverage

This research report categorizes the Bispecific Antibodies Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Mechanism of Action
    • Dual Antigen Targeting
    • Dual-Blocking Antibodies
    • T-cell Engagers
  • Therapeutic Area
    • Autoimmune Diseases
    • Infectious Diseases
    • Neurological Disorders
    • Oncology
  • End-user
    • Hospitals & Specialist Clinics
    • Research Institutions & Academic Centers
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Bispecific Antibodies Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Bispecific Antibodies Market?

3. What are the technology trends and regulatory frameworks in the Bispecific Antibodies Market?

4. What is the market share of the leading vendors in the Bispecific Antibodies Market?

5. Which modes and strategic moves are suitable for entering the Bispecific Antibodies Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of cancer and other chronic illnesses globally
      • 5.1.1.2. Advancements in genetic engineering and protein engineering technologies
      • 5.1.1.3. Growing regulatory support for innovative therapies for the development and approval of novel bispecific antibodies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost regarding the development of bispecific antibodies
    • 5.1.3. Opportunities
      • 5.1.3.1. Expanding usage of bispecific antibodies in the treatment of rare diseases
      • 5.1.3.2. Rising investments in healthcare infrastructure and research & development activities by pharmaceutical companies
    • 5.1.4. Challenges
      • 5.1.4.1. Manufacturing complexities associated with bispecific antibodies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Mechanism of Action: Increasing preference for dual antigen targeting for minimizing off-target effects
    • 5.2.2. Therapeutic Area: Expanding application of bispecific antibodies in oncology for engaging and destroying cancer cells
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Bispecific Antibodies Market, by Mechanism of Action

  • 6.1. Introduction
  • 6.2. Dual Antigen Targeting
  • 6.3. Dual-Blocking Antibodies
  • 6.4. T-cell Engagers

7. Bispecific Antibodies Market, by Therapeutic Area

  • 7.1. Introduction
  • 7.2. Autoimmune Diseases
  • 7.3. Infectious Diseases
  • 7.4. Neurological Disorders
  • 7.5. Oncology

8. Bispecific Antibodies Market, by End-user

  • 8.1. Introduction
  • 8.2. Hospitals & Specialist Clinics
  • 8.3. Research Institutions & Academic Centers

9. Americas Bispecific Antibodies Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Bispecific Antibodies Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Bispecific Antibodies Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. AstraZeneca aims for '2.0' cancer pipeline, shares bispecific data
    • 12.3.2. U.S. FDA Approves TALVEY(TM) (talquetamab-tgvs), a Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
    • 12.3.3. Pfizer's Elranatamab Receives FDA and EMA Filing Acceptance
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. BISPECIFIC ANTIBODIES MARKET RESEARCH PROCESS
  • FIGURE 2. BISPECIFIC ANTIBODIES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. BISPECIFIC ANTIBODIES MARKET DYNAMICS
  • FIGURE 7. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. BISPECIFIC ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. BISPECIFIC ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BISPECIFIC ANTIBODIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY DUAL ANTIGEN TARGETING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY DUAL ANTIGEN TARGETING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY DUAL-BLOCKING ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY DUAL-BLOCKING ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY T-CELL ENGAGERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY T-CELL ENGAGERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY HOSPITALS & SPECIALIST CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY HOSPITALS & SPECIALIST CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTIONS & ACADEMIC CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTIONS & ACADEMIC CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 32. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 33. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 34. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 37. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 38. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 39. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 40. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 41. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 42. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 43. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 44. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 45. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 46. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 47. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 48. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 49. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 50. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 51. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 52. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 53. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 54. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 55. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 56. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 57. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 58. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 59. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 60. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 61. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 62. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 63. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 64. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 65. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 66. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 69. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 70. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 80. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 82. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 84. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 85. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 86. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 87. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 88. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 89. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 90. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 91. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 92. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 93. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 94. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 95. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 96. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 97. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 98. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 99. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 100. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 101. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 102. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 103. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 104. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 105. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 106. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 107. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 108. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 109. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 110. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 111. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 112. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 113. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 114. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 116. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 118. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 120. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 121. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 122. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 123. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 124. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 125. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 126. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 128. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 130. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 132. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 133. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 134. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 135. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 136. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 137. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 138. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 139. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 140. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 141. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 142. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 143. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 144. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 145. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 146. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 147. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 148. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 149. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 150. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 159. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 160. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 161. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 162. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 163. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 164. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 165. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 166. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 167. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 168. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 169. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 170. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 171. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 172. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 173. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 174. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 175. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 176. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 177. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 178. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 179. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 180. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 181. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 182. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 183. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 184. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 185. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 186. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 187. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 188. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 189. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 190. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 191. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 192. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 193. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 194. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 195. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 196. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 197. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 198. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 199. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 200. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 202. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 204. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 206. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 207. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 208. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 209. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 210. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 211. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 212. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 213. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 214. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 215. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 216. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 217. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 218. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 219. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 220. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 221. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 222. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 223. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 224. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 225. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 226. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 227. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 228. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 229. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 230. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 231. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 232. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 233. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 234. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 235. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 236. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 238. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 240. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 242. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 244. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 248. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 249. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 250. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 251. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 252. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 253. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 254. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 255. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 256. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 257. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 258. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 259. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 260. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 262. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 264. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 266. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 267. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 268. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 269. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 270. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 271. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 272. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 284. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 285. BISPECIFIC ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 286. BISPECIFIC ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023